Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Harmony Biosciences Holdings, Inc. - Common Stock
(NQ:
HRMY
)
35.24
-0.62 (-1.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Harmony Biosciences Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript
↗
February 25, 2025
HRMY earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
February 25, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Earnings Scheduled For February 25, 2025
↗
February 25, 2025
Via
Benzinga
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
↗
February 19, 2025
Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a Phase 3 trial planned for late 2025.
Via
Benzinga
Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug
↗
February 19, 2025
The agency rejected the drug in the application filing stage, which is earlier than usual.
Via
Investor's Business Daily
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
February 19, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Demystifying Harmony Biosciences: Insights From 5 Analyst Reviews
↗
February 11, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
↗
January 16, 2025
Via
Benzinga
While growth is established for NASDAQ:HRMY, the stock's valuation remains reasonable.
↗
February 18, 2025
HARMONY BIOSCIENCES HOLDINGS could be undervalued. NASDAQ:HRMY is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.
Via
Chartmill
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
February 18, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
NASDAQ:HRMY, a growth stock which is not overvalued.
↗
January 28, 2025
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing.
Via
Chartmill
Friday's after hours session: top gainers and losers
↗
January 24, 2025
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
NASDAQ:HRMY is not too expensive for the growth it is showing.
↗
December 16, 2024
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing.
Via
Chartmill
Analyst Expectations For Harmony Biosciences's Future
↗
October 29, 2024
Via
Benzinga
Earnings Outlook For Harmony Biosciences
↗
October 28, 2024
Via
Benzinga
Breaking Down Harmony Biosciences: 6 Analysts Share Their Views
↗
October 02, 2024
Via
Benzinga
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
↗
January 17, 2025
Many stocks flashed buy signals as the major indexes rose to or above key levels.
Via
Investor's Business Daily
Topics
Economy
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
↗
January 13, 2025
Some companies saw their shares skyrocket on preliminary reports, but others took hits.
Via
Investor's Business Daily
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
January 13, 2025
From
Harmony Biosciences
Via
Business Wire
Unveiling 6 Analyst Insights On Harmony Biosciences
↗
September 10, 2024
Via
Benzinga
Investors should take note of NASDAQ:HRMY, a growth stock that remains attractively priced.
↗
January 07, 2025
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
Don't overlook NASDAQ:HRMY—it's a hidden gem with strong fundamentals and an attractive price tag.
↗
January 03, 2025
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), an undervalued stock with good fundamentals.
Via
Chartmill
Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
December 17, 2024
Via
ACCESSWIRE
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
December 16, 2024
Via
ACCESSWIRE
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
December 13, 2024
Via
ACCESSWIRE
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
↗
October 30, 2024
Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders.
Via
Benzinga
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
↗
October 29, 2024
HRMY earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
↗
October 29, 2024
The company is focused on developing its pipeline of sleep and epilepsy drugs.
Via
Investor's Business Daily
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
↗
September 10, 2024
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026.
Via
Benzinga
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript
↗
August 06, 2024
HRMY earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
